



SEMPERIT GROUP FY 2021 INVESTOR PRESENTATION

Karl Haider, CEO

Petra Preining, CFO

Kristian Brok, COO

23 March 2022



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.27)



FY 2021 Highlights



Another record result in 2021 despite considerable cost inflation, scarcity of raw materials, energy as well as logistics



Industrial Sector: strong sales and order book; improved performance against headwinds – close collaboration of supply chain management, procurement, R&D and production



Proactive working capital management resulted in improvement of working capital as % of LTM revenues versus 2019 and 2020



Sharp price decline for protective gloves after reaching the plateau in Q2'21, albeit still at above pre-corona level at year-end



Strong cash flow generation supports aspiration for future organic and inorganic growth





Agenda

Key Highlights (p.2)

Operational Performance (p.4)


Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.27)



Industrial Sector exceeding pre-corona level: higher top-line growth against margin pressure




- Revenues increased by 16% yoy, gap of EBITDA in absolute terms closed and is now up by 7% yoy
- Sales price increases offset price inflation from raw materials, energy and logistics




Semperflex FY 2021

Proactive price increases support revenues and margins

Semperflex



FY 2021 vs. FY 2020



- Order book and revenues exceed pre-corona level despite regional differences
- Strong operating performance against limited availability of raw materials, cost inflation for raw materials, energy and logistics as well as supply chain disruptions
- Margin development: trade-off between cost optimisation and reliable fulfilment of orders
- Successful ramp up of production in Odry (CZ) in H2'21







Sempertrans FY 2021

Headwinds from Covid impact, delayed investment decisions by customers and price increases

Sempertrans



FY 2021 vs. FY 2020



- Higher raw material's cost levels result in market recovery of mining industry, subsequently stimulating new investments and maintenance
- Order book almost doubled compared to YE 2020: replacement orders increased, major replacements & new projects expected to pick up in 2022
- EBITDA decline in 2021 mainly caused by volume deviation and price pressure on raw materials & logistics
- Segment receives highest management attention



¹ Q1'19 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China



² Q3'21 EBITDA: positive effect of € 3.7m from recycling of foreign exchange differences




Sempers seal FY 2021

Top-line growth hampered by input cost inflation


Sempers seal



FY 2021 vs. FY 2020



- Order intake above 2020 throughout 2021, order book well above YE 2020 at YE 2021
- Strong top-line and EBITDA growth – both above pre-corona level of 2019
- Continued pressure of high raw material costs impact EBITDA, EBIT and margins despite proactive price increases
- Excellent performance in delivery and reliability








Semperform FY 2021

Continuing top-line growth – with different product mix

Semperform



FY 2021 vs. FY 2020



- Strong order intake results in improved order book level vs YE 2020
- Strong turnover and output growth
- Regional portfolio expansion in progress
- Product mix change with lower share of high-margin businesses (ski tourism) and higher costs lead to lower margins in 2021
- Top-line growth at handrail and SES (Engineered Solutions) exceeded 2020, especially in railway, piping and household industries







Medical Sector / Sempermed segment FY 2021

Price decline after reaching a plateau in Q2'21, yet still the best result in Sempermed's history

Sempermed



FY 2021 vs. FY 2020



- Change in market dynamics: general decrease of demand and higher total capacities available in the market
- Strong price levels in H1'21 followed by a sharp decline in H2'21 – at YE still above pre-corona level
- Sharp margin decline aggravated by headwinds in raw materials and logistics
- Strong order book – above pre-corona level
- P7+ plant ramp up started in Q4'21 – future gross capacity increase by 18%



¹ Q3'19 EBITDA adjusted for € 4m due to the positive effect from the release of provision in Sempermed for Brazilian court case for tax liabilities



Proactively tackling cost pressure and supply chain disruption

Headwinds

Cost inflation and limited availability of raw materials and consumables

Costs and logistical planning of transport and container shipping

Rising energy prices since H2'21

Shortage of qualified labour and wage pressure

Countermeasures

- **Strong and flexible collaboration of supply chain management, procurement, R&D and production**
- **Further increased operational efficiency**
- **Energy**
 - **Reductions in energy consumption due to efficiency increase**
 - **Selective pre-contracting**
- **Global multiple sourcing of raw materials**
- **Improved service levels**
- **Consequential sales price increases**





Unprecedented raw materials price inflation

- Higher raw material and logistics costs consistently throughout 2021 recently further exacerbated due to the war in Ukraine
- Continuing operational efficiency measures seeking to offset total cost increases
- Further focus on global multiple sourcing

Price indices Butadiene
(as main raw material for
synthetic rubber / latex)

Price index LFO-F-NWE

Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2020 = 100.0



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.27)



FY 2021 Financial Highlights



Price inflation and disruption due to raw materials and logistics throughout 2021 further aggravated by cost pressure in Q4'21



Active working capital management remains the key focus despite increasing headwinds since H2'21



CAPEX increase to support future growth potential despite logistical constraints for investment goods



Robust balance sheet and strong cash flow generation support aspiration for future organic and inorganic growth



Operational efficiency and cost focus remain key management measures to tackle cost pressure in raw materials, energy, logistics and labour




2022 EBITDA is expected to be significantly below average market consensus due to Russia-Ukraine conflict (as of early March 2022)





Revenue development




% change of each segment / sector refers to 2021 vs. 2020.



Top-line growth translates into higher reported EBITDA

Another strong year for Medical Sector and resilient Industrial Sector

in € m




FY 2020 Semperfex Sempertrans Semperséal Semperform Sempermed Corporate **FY 2021**

EBITDA FY 2020	208.6	41.9	8.7	11.0	15.0	150.4	-18.4	
EBITDA FY 2021		51.3	6.8	11.6	12.4	301.1	-21.5	361.8
EBITDA margin FY 2021		21.3%	6.6%	9.6%	13.7%	48.1%	–	30.6%



Major drivers of strong operating performance

Proactive price increases more than offset cost inflation





Overview of key financial KPIs, 2019 – 2021

	2019	2020	2021
EBITDA, in € m	67.8	208.6	361.8
EBITDA margin, in %	8.1	22.5	30.6
EBIT, in € m	-16.5	237.8	315.0
EBIT margin, in %	-2.0	25.6	26.6
Earnings after tax, in € m	-44.9	194.6	247.5
Free Cashflow, in € m	60.8	176.2	241.2
CAPEX, in € m	31.9	26.4	47.9




Quarterly CAPEX development 2020-2021

- CAPEX increased against its low level in 2020
- Outlook 2022: planned to be approximately at 2021 level
- Industrial Sector is started to invest in growth CAPEX

CAPEX per segment


in € m





Free cash flow development

- Further improved operating cash flow
- Operating CF driven by strong performance but also impacted by working capital requirements
- Free CF on record level






Working Capital overview

Components of Working Capital

in € m




¹⁾ Trade Working Capital in % of LTM revenues



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 31/12/2021: € 959m
Balance sheet 31/12/2020: € 764m



Financial profile as of 31 December 2021


- **Cash and cash equivalents** € 236m
- **Unused credit facilities** total € 90m
- **Corporate Schuldschein loan** at € 86m
- **Net debt turns to net cash** at € 144m, Net debt / EBITDA below zero (YE'20: 0.1x)
- **Equity ratio** of 56.3% (YE'20: 43.5%)
- **Dividend:** € 1.50 per share will be proposed to the Annual General Meeting



Capital allocation priorities and consistent strategic ambition

Vision: Global polymer engineering company – application focused and >1bn sales

Strategic Priorities





Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.27)



Management Agenda and Assumptions for 2022



Starting base line in 2022

Protective glove prices clearly declining from plateau in Q2'21

Focus on strategic growth of the Industrial Sector

Strict cost management to maintain competitive position

Further acceleration due to geopolitical crisis: increased mobilisation of solution oriented capabilities

Expectations for 2022

Strong focus on internal management capability against exogenous factors (raw materials, energy, logistics and labour)

Geopolitical crisis has worsened the availability of raw materials and increased the need for higher inventory buffers

Market dynamics might deviate from common assumptions

Semperit maintains its customer promise of reliability and quality of service

Consequently, 2022 EBITDA is expected to be significantly below average market consensus (early March '22 € 100-120m) due to Russia-Ukraine conflict





Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Am Belvedere 10
1100 Vienna, Austria

Financial Calendar 2021

23.3.2022	Publication of 2021 annual financial statements
27.4.2022	Annual general meeting, Vienna
18.5.2022	Report on Q1 2022
17.8.2022	Half-year financial report 2022
16.11.2022	Report on Q1-3 2022

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.24)

Appendix (p.27)



Sectors and Group: FY 2021 vs FY 2020

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	FY 2021	FY 2020	%	FY 2021	FY 2020	%	FY 2021	FY 2020	%
Revenue	556.1	478.4	+16.2%	626.1	449.2	+39.4%	1,182.2	927.6	+27.4%
EBITDA	82.1	76.6	+7.2%	301.1	150.4	>100%	361.8	208.6	+73.5%
EBITDA margin	14.8%	16.0%	-1.2 PP	48.1%	33.5%	+14.6 PP	30.6%	22.5%	+8.1 PP
EBIT	56.8	32.4	+75.0%	280.9	224.9	+24.9%	315.0	237.8	+32.5%
EBIT margin	10.2%	6.8%	+3.4 PP	44.9%	50.1%	-5.2 PP	26.6%	25.6%	+1.0 PP
Earnings after tax	-	-	-	-	-	-	247.5	194.6	+27.2%
Earnings per share in EUR	-	-	-	-	-	-	11.99	9.06	+32.3%
Additions in tangible and intangible assets	28.7	22.5	+27.7%	24.9	5.0	>100%	56.4	28.5	+98.1%
Employees	3,764	3,465	+8.6%	3,038	3,337	-9.0%	6,948	6,943	+0.1%

Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019 adj. ²⁾	FY 2019	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 adj.	FY 2020 adj. ⁵⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
Revenue	212.9	224.4	214.9	188.3	840.6	199.1	219.8	238.2	270.5	927.6	323.1	337.7	265.3	256.1	1,182.2
EBITDA	16.5	22.7	17.3	7.4	63.8	16.9	40.7	60.9	90.0	208.6	122.2	125.3	76.8	37.5	361.8
EBITDA margin	7.7%	10.1%	8.0%	3.9%	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%	37.1%	28.9%	14.6%	30.6%
EBIT	7.8	13.1	8.1	-0.7	28.2	9.8	33.6	49.2	78.8	171.4	110.8	113.8	65.4	25.0	315.0
EBIT margin	3.7%	5.8%	3.8%	-0.4%	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%	33.7%	24.7%	9.8%	26.6%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. ²⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations ³⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) ⁴⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ⁵⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million)



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
in EUR m															
Revenue	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9	54.7	59.7	57.7	68.4	240.5
EBITDA	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9	12.3	13.9	11.2	13.9	51.3
EBITDA margin	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%	23.3%	19.3%	20.4%	21.3%
EBIT	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7	4.5	30.9	9.6	11.1	8.4	11.0	40.0
EBIT margin	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%	18.5%	14.5%	16.1%	16.6%

Sempertrans (Conveyor belts)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 ³⁾	FY 2020 adj. ⁴⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
in EUR m															
Revenue	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1	26.9	24.2	28.0	25.3	104.5
EBITDA	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7	1.0	0.8	4.7	0.4	6.8
EBITDA margin	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%	3.3%	16.7%	1.4%	6.6%
EBIT	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-0.6	4.9	0.2	-0.1	3.8	-0.7	3.2
EBIT margin	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%	-0.2%	13.6%	-2.9%	3.1%

¹⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect: EUR 20.0 million).

²⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

³⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁴⁾ 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



Semperform and Semperséal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020

in EUR m	FY 2017 adj.	Q1 2018	Q2 2018	Q3 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	185.0	47.5	50.7	50.3	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	21.5	4.5	7.3	6.2	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	11.6%	9.6%	14.4%	12.2%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	13.3	2.4	5.1	4.2	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	7.2%	5.0%	10.1%	8.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Semperform (Window and door profiles, Handrails) - after 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8	19.8	23.6	23.3	23.9	90.6
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0	3.1	3.6	3.3	2.5	12.4
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%	15.2%	14.1%	10.3%	13.7%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3	2.1	2.6	2.3	1.4	8.5
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%	11.2%	10.0%	6.0%	9.4%

Semperséal (Profiles and Rubber Sheeting) starting in 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6	28.7	30.3	32.4	29.1	120.5
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0	4.2	2.4	4.1	0.9	11.6
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%	7.9%	12.6%	3.0%	9.6%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1	2.6	0.8	2.5	-0.9	5.1
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%	2.6%	7.7%	-3.1%	4.2%

Split of former Semperform into Semperséal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)															
in EUR m	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019	FY 2019 ²⁾	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 ⁵⁾	FY 2020 adj. ⁶⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021
Revenue	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4	161.1	449.2	192.9	199.8	124.0	109.4	626.1
EBITDA	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4	83.0	150.4	105.3	115.3	56.9	23.7	301.1
EBITDA margin	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%	51.5%	33.5%	54.6%	57.7%	45.9%	21.7%	48.1%
EBIT	-2.8	-1.4	-0.3	-0.9	-5.5	4.4	17.6	38.9	77.8	138.7	100.2	110.3	52.1	18.3	280.9
EBIT margin	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%	52.0%	55.2%	42.0%	16.7%	44.9%

¹⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

²⁾ 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

³⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁴⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁵⁾ Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁶⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



Key figures 2011-2021

Key performance figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾	2019 adj. ⁷⁾	2020 adj. ⁸⁾	2021
Revenue	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6	1,182.2
EBITDA	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	361.8
EBITDA margin	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	30.6%
EBIT	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	315.0
EBIT margin	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	26.6%
Earnings after tax	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9	247.5
EPS²⁾, in EUR	2.52	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	11.99
Gross cash flow	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7	323.4
Return on equity	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%

Balance sheet key figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018	2019	2020	2021
Balance sheet total	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4	958.6
Equity²⁾	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1
Equity ratio	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%
Investments in tangible and intangible assets	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	47.9
Employees, at balance sheet date, FTEs	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	6,948

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18). ²⁾ 2014 and 2015 restated. ³⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁴⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁵⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). ⁶⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



Price index wire rod



Ø YTD 2022

¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2021

in EUR m

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed	
Revenue	1.182.2	240.5 / 20% ¹⁾	104.5 / 9% ¹⁾	90.6 / 8% ¹⁾	120.5 / 10% ¹⁾	626.1 / 53% ¹⁾
EBITDA	361.8 ²⁾	51.3	6.8	12.4	11.6	301.1
Employees	6,948 ²⁾	1,753 / 25% ³⁾	921 / 13% ³⁾	576 / 8% ³⁾	514 / 7% ³⁾	3,038 / 44% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe
6 position globally



Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of polymer and plastics (handrails, cable car rings, ski foils and Engineered Solutions)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting (construction, packaging, machinery, HVAC, marine, electric systems)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe




*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.
²⁾ Group figure includes corporate center of € -21m, 147 employees.
³⁾ Employees in % of Group employees.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C